In this interview, we conversed with Pete Govorchin, President, City of Hope® Cancer Center Chicago and Edward S. Kim, M.D., M.B.A., Vice Physician-in-Chief, City of Hope National Medical Center, and System Director, Clinical Trials, about the Illinois Cancer Patients Bill of Rights, a groundbreaking initiative aimed at enhancing access to advanced cancer care, especially for underserved populations. The dialogue delved into systemic healthcare barriers, the integration of clinical trials, and the future of decentralized trials in democratizing access to cutting-edge treatments.
Moe: The Illinois Cancer Patients Bill of Rights is a major policy step. How do you ensure it leads to real improvements in access to advanced cancer care for underserved groups?
Pete Govorchin: This resolution is a foundational step in uniting organizations like Susan G. Komen and the American Cancer Society to establish core values for cancer patient care. It’s about creating a unified front to advocate for patient rights and implementing these principles effectively. However, more work must be done to see these values reflected in real-world outcomes. For instance, by collaborating with these organizations, we aim to create a framework that not only sets standards but also actively works to dismantle barriers to care. We believe that by fostering a collaborative environment, we can drive meaningful change and ensure that the principles of the Bill of Rights are not just theoretical but are actively improving patient experiences and outcomes.
Moe: What are the biggest structural barriers in Illinois’ healthcare that could hinder this bill’s goals, and how do you plan to address them?
Pete Govorchin: Education and trust are significant barriers. Many communities lack awareness of available treatment options and face logistical challenges like transportation. We aim to partner with local organizations to build trust and educate these communities, making them aware of their rights and available resources. For example, by alleviating transportation issues through our sophisticated programs, we can ensure that logistical hurdles do not deter patients. Also, fostering trust through community partnerships is crucial, especially in areas where medical institutions are viewed skeptically. By working closely with these communities, we can break down barriers and create a more inclusive healthcare environment that genuinely serves the needs of all patients.
Moe: Cancer patients from underserved communities face barriers to clinical trials. Are there initiatives to reduce these barriers and increase diverse participation?
Ed Kim: Absolutely. It’s about creating a coalition of advocacy groups to educate and empower communities. By bringing our expertise to the Chicago area, we’ve expanded access to advanced care and clinical trials, making it more convenient for those not near major cancer centers. This approach increases participation and ensures that trials are more representative of the diverse populations we serve. By decentralizing access points, we can better integrate these communities into the research process, ultimately leading to more inclusive and effective treatments. We aim to make clinical trials accessible to everyone, regardless of location or background.
Moe: What are the most pressing disparities in cancer care, and how does this Bill of Rights address these challenges?
Ed Kim: Education and access are key. Many feel stuck with limited options. Growing up in a small town, I understand the geographical challenges. We’re working to make expert care accessible and inclusive, ensuring clinical trials reflect real-world demographics. The Bill of Rights catalyzes change, emphasizing the need for equitable access and encouraging systemic shifts in care delivery. By focusing on education and awareness, we aim to empower patients to seek the best possible care, regardless of their location or socioeconomic status. This initiative is about leveling the playing field and ensuring everyone can benefit from the latest advancements in cancer treatment.
Moe: How can smaller community oncology clinics be integrated into clinical research to expand access?
Ed Kim: We’re creating a national clinical trial system, a first of its kind, to connect regional sites with cutting-edge trials. This system will bring advanced treatments closer to patients, reducing the need for long-distance travel to large academic centers. We can create a seamless network supporting patients and researchers by leveraging technology and fostering partnerships with local clinics. This integration enhances access and enriches the data collected, leading to more robust and applicable research outcomes. Our vision is to create a national system that democratizes access to clinical trials and ensures that all patients can benefit from the latest innovations in cancer care.
Moe: How is City of Hope adapting to decentralized and hybrid clinical trials, and what are the opportunities and challenges in using digital health tools?
Ed Kim: While digital tools are valuable, we can’t disconnect from the human touch. Our patient-centric model allows for remote follow-ups and local lab tests once patients are stable. It’s a hybrid approach, ensuring safety and quality while expanding access. The challenge lies in balancing technology with personal interaction, especially in communities with limited digital infrastructure. By adopting a hybrid model, we can offer flexibility and convenience without compromising the quality of care or the integrity of the research. We aim to use technology to enhance the patient experience, not replace the essential human elements of care.
Moe: Despite the passage of this bill, what policy gaps still exist, and what changes are needed?
Ed Kim: Streamlining the approval process is crucial. It reduces patient anxiety and allows us to focus on care. Cancer care is complex, with new therapies emerging rapidly. We need policies that support timely access to these innovations. The current system often involves lengthy approval processes that can delay treatment. By advocating for policy changes that prioritize patient needs and reduce bureaucratic hurdles, we can enhance cancer care delivery’s overall efficiency and effectiveness. Our focus is on creating a system that is responsive to the needs of patients and capable of adapting to the rapid pace of medical advancements.
Moe: With the new administration’s stance on DEI initiatives, how do you ensure equitable access to cancer care remains a priority?
Pete Govorchin: Access to cancer care should be available to all. The demographics of clinical trial participants don’t reflect the country’s diversity, and that’s a problem we must address. Our mission to cure cancer and provide inclusive research remains unchanged. Our commitment to diversity and inclusion in research is unwavering regardless of political shifts. By focusing on our patients’ science and needs, we can continue to drive progress and ensure that all individuals have access to the best possible care. Our dedication to these principles is a core part of our identity and mission at City of Hope.
Ed Kim: Cancer is our enemy, and curing it is our North Star. Inclusive research serves the population, and we’ll continue to push science forward regardless of political changes. Our focus is on the patients and the science, ensuring that our efforts are aligned with the ultimate goal of eradicating cancer and improving lives. We are committed to making sure that our research and clinical trials are accessible to everyone and that we are doing everything we can to eliminate disparities in cancer care.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
